RenovoRx, Inc. RNXT
1.12 USD -0.07 (-6.30%)
Nov 6, 2026, 2:47 PM EST
0.88 Day range 1.21
0.701 52-week range 2.59
- YTD
- +32.74%
- 1 year
- +15.42%
- Market cap
- 50.32M
- EPS (ttm)
- -0.31
- Shares out
- 24.00M
- Forward P/E
- -3.10
- YTD return
- +32.74%
- 1-year return
- +15.42%
- Volume
- 1.52M
- Avg volume
- 797.77K
- Open
- 1.05
- Previous close
- 1.19
- Day's range
- 0.88 – 1.21
- 52-week range
- 0.701 – 2.59
- Beta
- 0.99
- Analysts
- Strong Buy
- Price target
- 5.50 (+393.3%)
- Earnings date
- Aug 13, 2024
5D -0.19 (-14.50%)
Key statistics
- Enterprise value
- 14.40M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.62M
- Total cash
- 11.74M
- Total debt
- 0
- Return on equity
- -155.12%
- Short % of float
- 0.31%
- 50-day average
- 1.14
- 200-day average
- 1.18
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 5.50 +393.3% upside
Now 1.12
- Target (low)
- 3.50
- Target (mean)
- 5.50
- Target (high)
- 9.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.12.
Financials — quick view
RNXT Revenue — quarterly 909.00K
RNXT Net income — quarterly -2.91M
RNXT EPS — quarterly -0.06
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.12 | -0.10 | +0.02 | +16.67% |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.10 | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | -0.07 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -0.17 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | Ascendiant Capital | main | Buy | Buy |
| Sep 12, 2024 | Ascendiant Capital | main | Buy | Buy |
| Jun 17, 2024 | Ascendiant Capital | init | — | Buy |
| Feb 2, 2024 | Alliance Global Partners | init | — | Buy |
| Nov 15, 2023 | Maxim Group | down | Buy | Hold |
| Aug 18, 2023 | Roth MKM | main | Buy | Buy |
About RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- renovorx.com
News
CORRECTION: RenovoRx Q3 Adj. EPS $(0.07) Misses $(0.06) Estimate, Sales $1.066M Beat $1.065M Estimate 
RenovoRx Q3 2026 Earnings Call Transcript 
RenovoRx Affirms FY2026 Sales Guidance of $3.750M-$4.250M vs $3.873M Est 
RenovoRx Q3 Adj. EPS $(0.08) Misses $(0.06) Estimate, Sales $1.066M Beat $1.065M Estimate 
12 Health Care Stocks Moving In Friday's After-Market Session 
RenovoRx Enrolls First Participant In PRISM-TAMP, “PDAC Regression And Intraoperative Surgical Margin With Neoadjuvant TAMP Study 
RenovoRx Announces Publication Of Peer-Reviewed Case Series In Case Reports In Oncology From Researchers At Hackensack Meridian Health’s Jersey Shore University Medical Center 
Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5 - 12 Health Care Stocks Moving In Tuesday's Intraday Session
RenovoRx Announces Publication Of Sub-Study Data From Its Ongoing Phase III TIGeR-PaC Clinical Trial In The Journal Cancer Chemotherapy And Pharmacology; Data Show Trans-Arterial Micro-Perfusion-Mediated Delivery Concentrated Chemotherapy At The Tumor Site, Extracting ~51% Of Drug Locally Before It Entered The Bloodstream, Meaningfully Lowering Systemic Exposure
Your note
Sign in to keep a note on RNXT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGAH RAMTIN M.D. | Officer and Director | Purchase | Jan 25, 2024 | 47,460 |
| BAGAI SHAUN R. | Chief Executive Officer | Purchase | Jan 25, 2024 | 292,540 |
| MACFARLANE KIRSTEN ANGELA | Director | Purchase | Jan 25, 2024 | 40,983 |
| MARTON LAURENCE | Director | Purchase | Jan 25, 2024 | 33,634 |
| NELMS ANGELA GILL | Chief Operating Officer | Purchase | Oct 2, 2023 | 1,100 |
| SPIEGEL ROBERT J | Director | Purchase | Jan 25, 2024 | 40,983 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bank of Montreal /CAN/ | 4.06% | 975,000 | 1.24M | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 1.31% | 315,192 | 400.29K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.97% | 232,937 | 295.83K | Sep 29, 2024 |
| Nixon Peabody Trust Company | 0.40% | 97,165 | 123.40K | Sep 29, 2024 |
| Millennium Management Llc | 0.34% | 82,353 | 104.59K | Sep 29, 2024 |
| Vanguard Group Inc | 0.24% | 56,737 | 72.06K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.57% | 137,402 | 174.50K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.24% | 56,737 | 72.06K | Sep 29, 2024 |
| Schwab Capital Trust-Total Stock Market Index Fund | 0.21% | 49,232 | 62.52K | Jul 30, 2024 |
| Fidelity Total Market Index Fund | 0.20% | 47,275 | 60.04K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 32,380 | 41.12K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 3,794 | 4.82K | Oct 30, 2024 |